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Background: Despite their pivotal roles in colorectal carcinogenesis, the interrelationship and prognostic
significance of beta-catenin alterations and microsatellite instability (MSI) in colorectal cancer (CRC) needs to be
further clarified. In this paper, we studied the associations between beta-catenin overexpression and MSI status with
survival from CRC, and with expression of p21, p27, cyclin D1 and p53, in a large, prospective cohort study.
Methods: Immunohistochemical MSI-screening status and expression of p21, p27 and p53 was assessed in tissue
microarrays with tumours from 557 cases of incident CRC in the Malmö Diet and Cancer Study. Chi Square and
Spearman’s correlation tests were used to explore the associations between beta-catenin expression, MSI status,
clinicopathological characteristics and investigative parameters. Kaplan-Meier analysis and Cox proportional hazards
modelling were used to assess the relationship between beta-catenin overexpression, MSI status and cancer specific
survival (CSS).
Results: Positive MSI screening status was significantly associated with older age, female sex, proximal tumour
location, non-metastatic disease, and poor differentiation, and inversely associated with beta-catenin
overexpression. Beta-catenin overexpression was significantly associated with distal tumour location, low T-stage
and well-differentiated tumours. Patients with MSI tumours had a significantly prolonged CSS in the whole cohort,
and in stage III-IV disease, also in multivariable analysis, but not in stage I-II disease. Beta-catenin overexpression was
associated with a favourable prognosis in the full cohort and in patients with stage III-IV disease. Neither MSI nor
beta-catenin status were predictive for response to adjuvant chemotherapy in curatively treated stage III patients.
P53 and p27 expression was positively associated with beta-catenin overexpression and inversely associated with
MSI. Cyclin D1 expression was positively associated with MSI and beta-catenin overexpression, and p21 expression
was positively associated with MSI but not beta-catenin overexpression.
Conclusions: Findings from this large, prospective cohort study demonstrate that MSI screening status in colorectal
cancer is an independent prognostic factor, but not in localized disease, and does not predict response to adjuvant
chemotherapy. Beta-catenin overexpression was also associated with favourable outcome but not a treatment
predictive factor. Associations of MSI and beta-catenin alterations with other investigative and clinicopathological
factors were in line with the expected.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
8778585058652609* Correspondence: sakarias.wangefjord@med.lu.se
1Department of Clinical Sciences, Division of Pathology, Lund University,
Skåne University Hospital, Lund 221 85, Sweden
Full list of author information is available at the end of the article
© 2013 Wangefjord et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Wangefjord et al. Diagnostic Pathology 2013, 8:10 Page 2 of 12
http://www.diagnosticpathology.org/content/8/1/10Background
Colorectal cancer (CRC) is the third most common can-
cer in men and the second most common cancer in
women worldwide. More than 1,2 million new cases are
diagnosed globally every year, with more than 600,000
related deaths in 2008 [1].
Colorectal carcinogenesis is a complex multistage
process involving multiple genetic alterations and at
least three distinct pathogenetic pathways have been
characterized: chromosomal instability (CIN), microsat-
ellite instability and CpG island methylator phenotype
(CIMP) [2,3].
The chromosomal instability pathway (CIN) is charac-
terized by karyotypic abnormalities, e.g. aneuploidy and
loss of heterozygosity, and certain mutations including
activation of K-ras and inactivation of APC, loss of p53,
and loss of heterozygosity for the long arm of chromo-
some 18. This pathway accounts for 65-70% of sporadic
CRC [4,5] and for cancers associated with familial aden-
omatous polyposis (FAP), constituting less than 1% of all
CRC [6].
Beta-catenin is a membrane-associated protein with
essential functions in the regulation of cellular adhesion
and as the major mediator of the Wnt-signaling path-
way. When Wnt-receptors are activated, kinases in the
APC complex are inhibited, leading to accumulation of
cytoplasmic beta-catenin and its translocation to the nu-
cleus. This facilitates the transcription of various target
genes, e.g. cyclin D1, hence contributing to tumour pro-
gression [7-11].
Despite its crucial role in colorectal carcinogenesis,
previous studies on altered beta-catenin expression as a
prognostic marker or predictor of chemotherapy re-
sponse in CRC have been conflicting [12-15].
The second pathway is initiated by germline mutations
in the mismatch repair (MMR) genes, e.g. MLH1,
MSH2, MSH6, and PMS2, or somatic tumour MLH1
promoter methylation, leading to microsatellite instabil-
ity (MSI). MSI is detected in 15-20% of all cases of CRC,
predominantly tumours located in the proximal colon,
and in almost all tumours from patients with hereditary
nonpolyposis colon cancer (HNPCC), accounting for 3-
5% of all CRC [16,17].
CRC patients with MSI tumours seem to have a sig-
nificantly better prognosis compared to those with MSS
in most studies, but might not benefit from adjuvant
fluorouracil (FU) treatment [16-22]. On a molecular
level, there is in vitro data supporting that an intact mis-
match repair system is required to induce apoptosis of
FU-modified DNA [23].
Finally, the CpG island methylator phenotype (CIMP)
provides a third pathway to CRC through predisposition
to epigenetic DNA hypermethylation, causing transcrip-
tional silencing of tumour supressor genes [24,25].The aim of the present study was to examine the prog-
nostic and treatment predictive significance of beta-
catenin overexpression and MSI screening status in
tumours from a large prospective CRC cohort (n = 557).
A secondary aim was to examine the associations of
beta-catenin alterations and MSI status with key cell
cycle regulators p53, p21, p27 and cyclin D1. In a previ-
ous study on tumours from this cohort, elevated cyclin
D1 expression was found to associate with a prolonged
survival, in particular in male patients [26].
Methods
Study group
The Malmö Diet and Cancer Study (MDCS) is a
population-based prospective cohort study with the pri-
mary aim to examine whether a Western diet rich in fat
and low in fruit and vegetables increases the risk of cer-
tain forms of cancer. Between 1991–1996, a total num-
ber of 30 446 individuals; 12 120 (39.8%) men and 18
326 (60.2%) women between 44–74 years where enrolled
(from a background population of 74 138) [27]. Until 31
Dec 2008, 626 incident cases of CRC had been registered
in the MDCS. Cases were identified from the Swedish
Cancer Registry up until 31 Dec 2007, and from The
Southern Swedish Regional Tumour Registry for the
period of 1 Jan - 31 Dec 2008. All tumours with available
slides or paraffin blocks were histopathologically re-
evaluated on haematoxylin and eosin stained slides.
Histopathological, clinical and treatment data were
obtained from the clinical and/or pathology records.
TNM staging was performed according to the American
Joint Committee on Cancer (AJCC). Information on vital
status and cause of death was obtained from the Swedish
Cause of Death Registry up until 31 Dec 2009. Follow-
up started at date of diagnosis and ended at death, emigra-
tion or 31 Dec 2009, whichever came first. None of the
CRC cases registered until 31 Dec 2008 was lost due to
emigration during follow-up. Median follow-up time was
3.35 years (range 0–17.69) for the full cohort (n = 626) and
6.05 years (range 1.03-17.69) for patients alive (n = 344).
Patient and tumour characteristics of the cohort have been
described in detail previously [26,28,29]. Ethical permis-
sion was obtained from the Ethics Committee at Lund
University for the MDCS (Ref. 51/90), and the present
study (Ref. 530/2008).
Tissue microarray construction
Cases with an insufficient amount of tumour material
were excluded, whereby a total number of 557 (89.0%)
tumours were suitable for tissue microarray (TMA) con-
struction. Areas representative of cancer were marked
on haematoxylin & eosin stained slides and TMAs were
constructed as previously described [26,28]. In brief, two
1.0 mm cores were taken from each tumour and
Figure 1 Distribution of the investigative markers in four cases. Immunohistochemical images from four different cases. 1. Female patient,
age 70, with T3N0M0 tumour in transverse colon; beta-catenin grade 1 (0-1-0), MSI, p53 negative, p21 = 2/1, p27 negative, cyclin D1 = 2/2. 2:
Female patient, age 77, with T4N1M1 tumour in descendent colon; beta-catenin grade 3 (0-1-2), MSS, p53 negative, p21 negative, p27 2/2, cyclin
D1 1/1. 3. Male patient, age 75, with T4NXM tumour in proximal colon; beta-catenin grade 5 (1-2-2), MSS, p53 positive, p21 negative, p27 4/3,
cyclin D1 3/2. 4. Male patient, age 68, with T2N2M0 rectal cancer; beta-catenin grade 3 (1-1-1), MSS; p53 positive, p21 negative, p27 3/3, cyclin D1
negative. A: staining of beta-catenin (membrane-cytoplasm-nucleus) and mismatch repair proteins MLH1, PMS2, MSH2 and MSH6. B: staining of
p53, p21 (fraction/intensity), p27 (fraction/intensity) and cyclin D1 (fraction/intensity).
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Table 1 Associations of MSI screening status and beta-catenin expression with clinicopathological characteristics
MSI screening status Beta-catenin score
n (%) MSS MSI P-value 0-1 2-3 4-5 P-value
438(85.0) 77(15.0) 159(30.2) 170(32.3) 198(37.6)
Age
<=75 308(70.3) 41(53.2) 0.003* 101(63.5) 123(72.4) 133(67.2) 0.561
>75 130(29.7) 36(46.8) 58(36.5) 47(27.6) 65(32.8)
Sex
Female 222(50.7) 50(64.9) 0.021* 87(54.7) 90(52.9) 100(50.5) 0.425
Male 216(49.3) 27(35.1) 72(45.3) 80(47.1) 98(49.5)
Tumour location
Proximal 107(24.5) 62(80.5) <0.001** 84(53.2) 50(29.4) 37(18.8) <0.001**
Transverse 12(2.8) 8(10.4) 11(7.0) 7(4.1) 5(2.5)
Descending 26(6.0) 1(1.3) 6(3.8) 11(6.5) 9(4.6)
Sigmoid 105(24.1) 3(3.9) 19(12.0) 31(18.2) 60(30.5)
Rectum 186(42.7) 3(3.9) 38(24.1) 71(41.8) 86(43.7)
Unknown 2 0 1 0 1
T stage
1 45(10.8) 3(3.9) 0.116 12(8.0) 11(6.9) 23(11.9) 0.039*
2 53(12.7) 7(9.2) 14(9.3) 21(13.1) 27(14.0)
3 257(61.5) 54(71.1) 99(66.0) 100(62.5) 119(61.7)
4 63(15.1) 12(15.8) 25(16.7) 28(17.5) 24(12.4)
missing 20 1 9 10 5
N stage
0 222(56.5) 54(72.0) 0.017* 84(57.5) 86(55.8) 109(60.9) 0.249
1 101(25.7) 12(16.0) 28(19.2) 44(28.6) 44(24.6)
2 70(17.8) 9(12.0) 34(23.3) 24(15.6) 26(14.5)
missing 45 2 13 16 19
M stage
0 352(81.7) 72(93.5) 0.010* 123(78.8) 140(83.3) 166(85.1) 0.131
1 79(18.3) 5(6.5) 33(21.2) 28(16.7) 29(14.9)
missing 7 0 3 2 3
Differentiation grade
High 28(6.5) 6(8.0) 0.003** 16(10.3) 8(4.8) 10(5.1) 0.016*
Intermediate 321(74.5) 40(53.3) 94(60.3) 115(69.3) 159(81.5)
Low 82(19.0) 29(38.7) 46(29.5) 43(25.9) 26(13.3)
missing 7 2 3 4 4
Vascular invasion
No 121(47.8) 26(57.8) 0.220 48(50.5) 33(36.3) 68(58.1) 0.177
Yes 132(52.2) 19(42.2) 47(49.5) 58(63.7) 49(41.9)
missing 185 32 64 79 81
Columnar percentage in parentheses. χ2-test of association was used for 2x2 tables and χ2-test for linear trend for tables with more than two rows and/or
columns. The categories marked as missing were not included in the analysis. *Significant at the 0.05 level. **Significant at the 0.01 level. N1 = 1-3 positive nodes,
N2= > 4 positive nodes. MSS =Microsatellite stable, MSI = Microsatellite unstable. Proximal colon = appendix, cecum, ascending colon, hepatic flexure; descending
colon = splenic flexure and descending colon.
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automated arraying device (TMArrayer, Pathology
Devices, Westminster, MD, USA). As demonstrated pre-
viously, there was no selection bias regarding the distri-
bution of clinicopathological characteristics between the
TMA cohort and the full cohort [28].
Immunohistochemistry and staining evaluation
For immunohistochemical analysis, 4 μm TMA-sections
were transferred to glass slides (Menzel Super Frost
Plus), dried at room temperature, and baked in a heated
chamber for 2 hours at 60°C. Deparaffinization and anti-
gen retrieval was performed using the PT Link system
(DAKO, Glostrup, Denmark) in a high pH buffer. Stain-
ing was performed in an Autostainer Plus (DAKO) with
monoclonal antibodies against p21 (clone SX118, DAKO)
diluted 1:25, p27 (clone SX53G8, DAKO) diluted 1:100,
and p53 (clone DO-7, DAKO) diluted 1:100, using a di-
amino-benzidine (DAB) based visualization kit (K801021-2,
Dako Denmark A/S). Counterstaining was performed using
Mayer’s hematoxylin. Immunohistochemical staining and
evaluation of cyclin D1 expression had been performed pre-
viously using a monoclonal anti-cyclin D1 antibody DSC-6
(DAKO) diluted 1:50 [26]. Nuclear expression of p21,
p27 and cyclin D1 was evaluated in a similar fashion,
taking both the fraction of positive cells and staining
intensity into account. Specifically, the nuclear staining in-
tensity was denoted as 0 (negative), 1 (weak), 2 (moderate)
or 3 (strong), and the proportion of positive tumour nuclei
as 0 (0 to 1%), 1 (2 to 25%), 2 (26 to 50%), 3 (51 to 75%)
and 4 (> 75%). p53 positivity was defined as > = 50%
tumour cells with strong nuclear staining intensity in acor-
dance with previous studies [30].
For definition of MSI screening status, immunohisto-
chemical staining for MLH1, PMS2, MSH2 and MSH6
was performed as previously described [29]. Immunohis-
tochemical stainings were evaluated as negative when all
tumour cells showed loss of nuclear staining. Surround-
ing stromal cells and tumour infiltrating lymphocytes
served as internal controls for each biopsy core. A nu-
clear reaction of tumour cells was assessed as a positive
staining. MSI screening status was evaluated using
monoclonal antibodies against MLH1 (Clone ES05,
DAKO, diluted 1 : 100), PMS2 (Clone A16–4, 556415,
BD Pharmingen, San Diego, CA, USA, diluted 1 : 300),
MSH2 (Clone FE11, NA27, Calbiochem, San Diego, CA,
USA, diluted 1 : 100), and MSH6 (EPR3945, Epitomics,
Burlingame, CA, USA, diluted 1 :100) as previously
described [31]. Immunohistochemical stainings were
evaluated as negative when all tumour cells showed loss of
nuclear staining. Surrounding stromal cells and tumour
infiltrating lymphocytes served as internal controls for
each biopsy core. Any nuclear reaction of tumour cells
was assessed as positive staining. Tumour samples lackingnuclear staining of MLH1, PMS2, MSH2 or MSH6 were
considered to have a positive MSI screening status, and
referred to as MSI, and tumours with negative MSI
screening status are referred to as MSS.
Immunohistochemical staining of beta-catenin was
performed with a monoclonal anti-beta-catenin anti-
body (# 610153 BD Pharmingen, San Diego, Ca, USA),
diluted 1:5000. The staining was evaluated as previously
described [32,33], whereby membranous staining was
denoted as 0 (present) or 1 (absent), cytoplasmic staining
intensity as 0–2 and nuclear staining intensity as 0–2.
The total score ranging from 0 (corresponding to mem-
brane staining only, as in normal colonic mucosa) to 5
(tumours with strong nuclear and cytoplasmic staining)
was then divided into three categories; 1 = score 0–1,
2 = score 2–3 and 3 = score 4–5).
All immunohistochemical stainings were evaluated by
two independent observers (SW and KJ), who were
blinded to clinical and outcome data. Scoring differences
were discussed in order to reach consensus.
Statistical analysis
Chi Square and Spearman’s correlation (R) tests were
used to explore the associations between clinicopatholo-
gical and investigative parameters. Kaplan-Meier analysis
and log rank test were used to illustrate differences in
cancer specific survival (CSS) according to beta-catenin
overexpression and MSI screening status. Cox regression
proportional hazards models were used for estimation of
hazard ratios (HRs) for death from CRC in both uni- and
multivariable analysis, adjusted for age, gender, T-stage,
N-stage, M-stage, differentiation grade and vascular inva-
sion. A backward conditional selection method was used
for variable selection by the model. All tests were two-
sided. A p-value of 0.05 was considered significant. All
statistical analyses were performed using IBM SPSS Statis-
tics version 20.
Results
Associations of MSI screening status and beta-catenin
overexpression with clinicopathological characteristics
and investigative factors
Representative immunohistochemical images of the in-
vestigative markers in tumours from four different cases
are shown in Figure 1A & 1B.
As seen in Table 1 there were significant associations
between MSI and older age, female sex, proximal
tumour location, non metastatic disease (N0,M0) and
low differentiation grade. Further, beta-catenin expres-
sion was associated with distal tumour location, less
advanced T-stage and intermediate or high tumour dif-
ferentiation grade.
Associations between beta-catenin overexpression,
MSI screening status and investigative factors are shown
Table 2 Associations of MSI screening status and beta-catenin expression with expression of p21, p27 and p53
MSI screening status Beta-catenin score
n (%) MSS MSI P-value 0-1 2-3 4-5 P-value
438(85.0) 77(15.0) 159(30.2) 170(32.3) 198(37.6)
P53 status
Negative 196(40.0) 62(80.5) <0.001** 101(65.2) 92(55.1) 76(38.6) <0.001**
Positive 230(54.0) 15(19.5) 54(34.8) 75(44.9) 121(61.4)
missing 12 0 4 3 1
Cyclin D1 fraction
0-1% 94(22.1) 2(2.6) <0.001** 36(23.4) 36(21.7) 31(15.8) 0.001**
2-25% 159(37.4) 26(34.2) 63(40.9) 65(39.2) 63(32.1)
26-50% 65(15.3) 16(21.1) 20(13.0) 29(17.5) 33(16.8)
51-75% 87(20.5) 25(32.9) 27(17.5) 32(19.3) 53(27.0)
>75% 20(4.7) 7(9.2) 8(5.2) 4(2.4) 16(8.2)
missing 13 1 5 4 2
Cyclin D1 intensity
Negative 94(22.1) 2(2.6) <0.001** 36(23.4) 36(21.7) 31(15.8) 0.085
Weak 154(36.2) 20(26.3) 51(33.1) 59(35.5) 68(34.7)
Moderate 129(30.4) 41(53.9) 49(31.8) 55(33.1) 68(34.7)
Strong 48(11.3) 13(17.1) 18(11.7) 16(9.6) 29(14.8)
missing 13 1 5 4 2
P27 fraction
0-1% 54(12.7) 24(31.2) 0.003** 43(27.9) 33(19.8) 8(4.1) <0.001**
2-25% 96(22.6) 14(18.2) 36(23.4) 43(25.7) 35(17.9)
26-50% 90(21.2) 16(20.8) 32(20.8) 40(24.0) 36(18.4)
51-75% 134(31.5) 15(19.5) 31(20.1) 36(21.6) 83(42.3)
>75% 51(12.0) 8(10.4) 12(7.8) 15(9.0) 34(17.3)
missing 13 1 5 3 2
P27 intensity
Negative 54(12.7) 24(31.2) <0.001** 43/27.9) 33(19.8) 8(4.1) <0.001**
Weak 96(22.6) 22(28.6) 46(29.9) 39(23.4) 37(18.9)
Moderate 142(33.4) 18(23.4) 50(32.5) 51(30.5) 62(31.6)
Strong 133(31.3) 13(16.9) 15(9.7) 44(26.3) 89(45.4)
missing 13 1 5 3 2
P21 fraction
0-1% 69(16.3) 3(3.9) 0.002** 25(16.2) 27(16.2) 25(12.9) 0.835
2-25% 233(55.1) 41(53.2) 81(52.6) 90(53.9) 112857.7)
26-50% 60(14.2) 18(23.4) 24(15.6) 28(16.8) 26(13.4)
51-75% 53(12.5) 13(16.9) 21(13.6) 16(9.6) 30(15.5)
>75% 8(1.9) 2(2.6) 3(1.9) 6(3.6) 1(0.5=
missing 15 1 5 3 4
P21 intensity
Negative 69(16.3) 3(3.9) <0.001** 25(16.2) 27(16.2) 25(12.9) 0.567
Weak 174(41.1) 24(31.2) 60(39.0) 63(37.7) 81(41.8)
Moderate 122(28.8) 36(46.8) 51(33.1) 52(31.1) 60(30.9)
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Table 2 Associations of MSI screening status and beta-catenin expression with expression of p21, p27 and p53
(Continued)
Strong 58(13.7) 14(18.2) 18(11.7) 25(15.0) 28(14.4)
missing 15 1 5 3 4
MSI screening status
MSS - - 109(72.7) 136(83.4) 184(95.8) <0.001**
MSI - - 41(27.3) 27(16.6) 8(4.2)
missing 9 7 6
Columnar percentage in parentheses. χ2-test of association was used for 2x2 tables and χ2-test for linear trend for tables with more than two rows and/or
columns. The categories marked as missing were not included in the analysis. *Significant at the 0.05 level. **Significant at the 0.01 level. MSS =Microsatellite
stable, MSI = Microsatellite unstable.
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with beta-catenin overexpression. MSI correlated signifi-
cantly to cyclin D1 expression (fraction and intensity),
p21 expression (fraction and intensity), and inversely
with p53 expression and p27 expression (fraction and in-
tensity). Beta-catenin overexpression correlated signifi-
cantly to p53 expression, cyclin D1 expression (fraction),
and p27 expression (fraction and intensity).
Association of MSI screening status and beta-catenin
overexpression with survival
Kaplan-Meier analysis showed significant correlations
between MSI and prolonged CSS in the whole cohort
(Figure 2A), and in stage III-IV disease (Figure 2E) but
not in stage I-II disease (Figure 2C). Beta-catenin over-
expression correlated significantly to a prolonged CSS in
stage III-IV disease only (Figure 2F).
Uni- and multivariable (adjusted for age, T-stage, N-
stage, M-stage, differentiation grade and vascular inva-
sion) Cox regression analysis confirmed the significant
correlation between MSI and an improved CSS, both in
the full cohort and in stage III-IV disease (Table 3).
Beta-catenin overexpression was also associated with an
improved CSS, in the full cohort and patients with stage
III-IV disease, although these associations were less sig-
nificant than for MSI status (Table 3). Notably, while
only reaching statistical significance in multivariable
analysis, the HRs for beta-catenin overexpression should
be considered as being similar in univariable and multi-
variable analysis (0.75 vs 0.70 in the full cohort and 0.73
vs 0.67 in stage III-IV disease).
Next, we examined the potential treatment predictive
value of MSI screening status and beta-catenin overex-
pression. Subgroup analysis of stage III disease patients
in strata according to adjuvant treatment (no treatment,
5-fluorouracil + leucovorin or 5-fluorouracil + leucovorin
+ oxaliplatin) revealed no significant correlations of MSI
or beta-catenin overexpression and CSS (Figure 3).
The prognostic and treatment predictive value of MSI
and beta-catenin overexpression did not differ according
to gender (data not shown). Similar trends for theprognostic and treatment impact of MSI status and
beta-catenin expression were seen for 5-year overall sur-
vival (data not shown).
Discussion
In this study we have demonstrated that positive MSI
screening status is associated with a more favourable
prognosis and certain clinicopathological characteristics
of CRC, i.e. older age, female sex, proximal tumour loca-
tion and low differentiation grade. This is accordant to
previous studies [16,17], thus consolidating our data.
The correlation between MSI and a prolonged CSS was
significant in both uni- and multivariable analysis for the
whole cohort and for stage III-IV disease, but not for
stage I-II disease. A possible interpretation of this obser-
vation could be that MSI reflects a less agressive pheno-
type, with an improved CSS even in the presence of
metastatic disease and despite adverse pathological char-
acteristics such as low differentiation grade.
Here, we could not demonstrate any association be-
tween MSI status and response to adjuvant treatment in
curatively treated patients with stage III disease. On one
hand, the subgroups available for analysis of the effects
of adjuvant treatment were rather small, thus limiting
statistical power. On the other hand, since this study
started already in the mid 90s, when adjuvant chemo-
therapy was not yet standard of care in Sweden, nearly
half of the curatively treated patients with stage III dis-
ease did not receive adjuvant treatment. Although treat-
ment predictive markers are best evaluated in a
controlled, prospective setting, the value of retrospective
analyses on tumours from less extensively treated
patients should not be underestimated.
Moreover, the feasibility of MSI as a predictor of
therapeutic response has been debated, and a recent
meta-analysis showed results concordant with ours, i.e.
no treatment predictive value of MSI status [34].
Beta-catenin overexpression was also associated with a
reduced risk of death in the full cohort and in patients
with stage III-IV disease, although these associations
were weaker than for MSI status. Previous studies on
Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 Associations between MSI screening status, beta-catenin overexpression and survival in all patients and in subgroups
according to disease stage. Kaplan-Meier analysis of colorectal cancer specific survival according to: (A) MSI screening status in the full cohort
(logrank p = 0.008**), (B) Beta-catenin score in the full cohort (logrank p = 0.116), (C) MSI screening status in stage I-II disease (logrank p =0.985),
(D) Beta-catenin score in stage I-II disease (logrank p =0.725), (E) MSI screening status in stage III-IV disease (logrank p =0.032*) and (F) Beta-
catenin score in stage III-IV disease (logrank p =0.034*).
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ing, with some studies reporting a favourable or no
prognostic value [14,35-38] and some an association
with poor clinical outcome [12,13,39,40]. Many factors
could explain the differing results regarding the prog-
nostic value of beta-catenin overexpression; e.g. intrinsic
tumour heterogeneity [41], different immunohistochem-
ical staining and visualization methods with varying
degrees of sensitivity, and lack of standardization of what
constitutes a “positive” or “negative” result. In many
cases, nuclear beta-catenin expression is predominantly
seen in the margin and not in the center of the tumour
[42]. Horst et al. postulated that lost beta-catenin regula-
tion is presented rather as an altered intratumoral distri-
bution of nuclear beta-catenin expression [43] and, in
light of this observation, the TMA-technique may not be
an ideal tool for its assessment. Moreover, the degree
and prognostic implications of beta-catenin activation
may differ in primary and metastatic CRC [44].
The herein observed inverse association between MSI
and beta-catenin overexpression is also in accordance
with previous studies [45,46]. Assuming that MSI status
and beta-catenin overexpression represent two different
pathways to colorectal tumorigenesis, it might be per-
ceived as contradictory that both reflect an improvedTable 3 Cox proportional hazards model for colorectal cancer
beta-catenin overexpression in the full cohort and in stage II
Full cohort
HR(95% CI) p-value N(
Univariable
MSS 1,00 0,010** 43
MSI 0,50(0,29-0,84) 7
Multivariable
MSS 1,00 0,010* 38
MSI 0,46(0,25-0,84) 7
Univariable
Bata-catenin low 1,00 0,056 2
Bata-catenin High 0,75(0,56-1,01) 2
Multivariable
Bata-catenin low 1,00 0,031* 2
Bata-catenin High 0,70(0,51-0,97) 2
*Significant at the 0.05 level. **Significant at the 0.01 level. P-value from multivariab
(0,1,2), M-stage (0, 1), differentiation grade (high-intermediate vs low) and vascular
catenin high = beta-catenin score 3–5.CSS. However, as these pathways are not mutually exclu-
sive and likely overlap, their complex interactions need
further study.
The associations between MSI and cell cycle regulators
cyclin D1 and p21 have been described previously
[47,48] but the underlying mechanisms still remain un-
clear. Similarly, the inverse associations of MSI tumours
with p53 mutation status and p27 expression are well
known [30,48]. The positive correlation between beta-
catenin overexpression and p53 status is also in line with
previous studies [14,39,45].
The observation of a positive association of cyclin D1
expression with MSI screening status and beta-catenin
overexpression, respectively, is in line with the previ-
ously demonstrated findings of cyclin D1 expression
being associated with a prolonged CSS [26]. Notably, the
beneficial prognostic value of high cyclin D1 expression
was only evident in male and not in female CRC patients
[26]. In this study, the prognostic and treatment predict-
ive value of MSI and beta-catenin overexpression did
not differ according to sex.
Since the MDCS is a population-based cohort study, a
potential selection bias compared with the general popu-
lation must be taken into consideration, but the distribu-
tion of TNM-stages at diagnosis is in line with thespecific survival related to MSI screening status and
I-IV disease
Stage III-IV disease
events) HR(95% CI) p-value n(events)
Univariable
8(157) 1,00 0,036* 201(122)
7(15) 0,46(0,23-0,95) 23(8)
Multivariable
9(137) 1,00 0,011* 185(107)
3(13) 0,33(0,14-0,78) 20(6)
Univariable
51(96) 1,00 0,063 112(72)
76(86) 0,73(0,52-1,02) 122(66)
Multivariable
23(80) 1,00 0,036* 98(60)
47(75) 0,67(0,46-0,97) 113(57)
le analysis adjusted for age (>/<=75 years), gender, T-stage (I-II, III, IV), N-stage
invasion (+/−/unknown). Beta-catenin low = beta-catenin score 0–2. Beta
Figure 3 (See legend on next page.)
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Figure 3 Associations between MSI screening status, beta-catenin expression and survival in stage III disease stratified according to
adjuvant therapy. Kaplan-Meier analysis of colorectal cancer specific survival according to (A) MSI screening status and no adjuvant treatment (logrank
p = 0.415), (B) Beta-catenin score and no adjuvant treatment (logrank p = 0.783), (C) MSI screening status and adjuvant FLV (5-fluorouracil + leucovorin )
(logrank p = 0.251), (D) Beta-catenin score and adjuvant FLV (logrank p = 0.927), (E) MSI screening status and adjuvant FLOX (5-fluorouracil + leucovorin +
oxaliplatin ) (logrank p = 0.871) and (F) Beta-catenin score and adjuvant FLOX (logrank p = 0.336).
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[26,28]. Notably, while the distribution of clinicopatholo-
gical factors and survival from the disease did not differ
between women and men [26], a recent study demon-
strated sex-related differences in the associations of an-
thropometric factors with CRC risk by TNM stage and
tumour location in the present cohort [49]. These find-
ings provide further evidence for colorectal cancer being
a disease in which the influence of sex hormones should
not be underestimated. Therefore, the prognostic and
treatment predictive value of investigative CRC biomar-
kers should always be considered in strata according to
gender. Moreover, it will be of interest to investigate the
influence of anthropometric, hormonal and life-style fac-
tors on risk of CRC defined by MSI status and beta-
catenin alterations in the present cohort.
Since the number of events was identical for CRC-
specific and overall survival in patients with metastatic
disease, as previously demonstrated [26], the use of
CRC-specific survival as primary endpoint in the sur-
vival analyses in this study should be a reasonable surro-
gate for cancer-specific outcome. Moreover, similar
survival trends were observed for 5-year overall survival.
Conclusions
In conclusion, the findings from this large cohort study
demonstrate that MSI screening status in colorectal cancer
is an independent prognostic factor, but not in localized
disease, and does not predict response to adjuvant chemo-
therapy. Despite its inverse correlation with MSI status, we
also observed a link between beta-catenin and prolonged
survival from colorectal cancer. Associations of MSI and
beta-catenin alterations with other investigative and clinico-
pathological factors were largely in line with the expected.
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